These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6805621)

  • 1. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of hydralazine, in conventional and slow-release preparations, during long-term treatment of primary hypertension.
    Lins LE; Berglund J; Eliasson K; Wernersson B
    Clin Ther; 1983; 5(3):251-9. PubMed ID: 6850719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hydralazine in arterial hypertension. Randomized, double-blind comparison between conventional and slow-release preparations].
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Ugeskr Laeger; 1980 Jul; 142(29):1862-5. PubMed ID: 6996259
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydralazine dose-response curve analysis.
    Graves DA; Muir KT; Richards W; Steiger BW; Chang I; Patel B
    J Pharmacokinet Biopharm; 1990 Aug; 18(4):279-91. PubMed ID: 2231320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
    Floras JS; Jones JV; Hassan MO; Sleight P
    Br Med J (Clin Res Ed); 1982 Nov; 285(6352):1387-92. PubMed ID: 6814568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propranolol-hydralazine combination in essential hypertension.
    Stevens JD; Binstok G; Mullane JF; Woods JW; Pittman AW; del Greco F; Huang C; Morledge JH
    Clin Ther; 1983; 5(5):525-39. PubMed ID: 6352036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients.
    Adir J; Janda SM; Curry CL; Taylor RE; Poku CD; Rotenberg KS
    Clin Ther; 1987; 9(6):640-50. PubMed ID: 3326679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.
    Wilcox RG; Mitchell JR
    Br Med J; 1977 Aug; 2(6086):547-50. PubMed ID: 329948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients.
    Jackson SH; Shepherd AM; Ludden TM; Jamieson MJ; Woodworth J; Rogers D; Ludden LK; Muir KT
    J Cardiovasc Pharmacol; 1990 Oct; 16(4):624-8. PubMed ID: 1706804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of hydralazine action in hypertension.
    O'Malley K; Segal JL; Israili ZH; Boles M; McNay JL; Dayton PG
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):581-6. PubMed ID: 1102235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydralazine and prazosin in the treatment of hypertension.
    Vandenburg MJ; Sharman VL; Wright P; Drew PJ; Barnes JN
    Br J Clin Pharmacol; 1983 Nov; 16(5):537-42. PubMed ID: 6357257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metoprolol administered once daily in the treatment of hypertension. A double-blind crossover comparison between conventional tablets and metoprolol Durules.
    Asplund J; Ohman P
    Ann Clin Res; 1981; 13 Suppl 30():30-6. PubMed ID: 7027891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained release metoprolol: a comparison with conventional formulation in the treatment of hypertension.
    Logan RL; Goldstraw PW; Kiddle GB; Flacks LM; Watt M
    N Z Med J; 1981 Jul; 93(687):1-2. PubMed ID: 7022275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension.
    Svetkey LP; Weinberger MH; Gavras H; Gavras I; Brown TS; Deterding J; Klotman PE
    J Clin Hypertens; 1987 Dec; 3(4):579-88. PubMed ID: 3330988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients.
    Christensen HR; Kampmann JP; Simonsen K
    J Hum Hypertens; 1991 Apr; 5(2):121-7. PubMed ID: 1830108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of once and twice daily administration of sotalol in the treatment of hypertension.
    Parvinen I; Paukkala E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):293-8. PubMed ID: 378671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.